Vorinostat, the first FDA-approved HDAC inhibitor, is used to treat cutaneous T-cell lymphoma (CTCL), inducing apoptosis, cell cycle arrest, and differentiation [69]. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.